Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2021 11:00 ET | Source: RadioMedix Inc.

RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit

Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for...
January 22, 2019 10:00 ET | Source: RadioMedix Inc.

RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.

Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
November 13, 2018 10:00 ET | Source: RadioMedix Inc.

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors

Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
January 10, 2018 05:00 ET | Source: RadioMedix Inc.

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors

Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
June 22, 2017 16:00 ET | Source: RadioMedix Inc.

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
November 01, 2016 01:00 ET | Source: RadioMedix Inc.

RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212

Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...